ArticleJournal of inflammation research2025
Huiyang Shengji Unguent Promotes Lymphangiogenesis and Wound Healing in Diabetic Chronic Wounds: Combined Insights from Proteomics and in vivo and in vitro Analyses.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the mechanism by which HYSJ unguent promotes lymphangiogenesis and improves the healing of diabetic chronic wounds (DCWs). Methods: The main components of HYSJ were identified by mass spectrometry. A mouse model with chronic skin ulcers was established. The ultrastructure and lymphatic drainage of lymphatic endothelial cells in wounds were examined. Lymphatic markers in wound tissues were detected, and proteomic and bioinformatics analyses were performed to identify differentially expressed proteins and associated pathways. In vitro, a high-glucose inflammatory environment that mimics DCWs was induced in human lymphatic endothelial cells (HLEC). HYSJ and caspase inhibitors were used for intervention. Diverse assays were conducted to assess HLEC function and activation of inflammatory cell death. Results: The primary constituents of HYSJ unguent included coclaurine, sinapine, and ononin, among others. HYSJ increased healing of DCWs in diabetic mice, protected lymphatic endothelial cells, restored lymphatic drainage in the wound, and upregulated expression of key lymphatic proteins. Numerous proteins, including TLR2, Myd88, STAT1, and inflammatory response-related proteins such as NLRP3, Caspase-1, GSDMD, were expressed differentially in mice. HYSJ unguent also stimulated expression of key lymphatic proteins in HLEC, protected cell function, and suppressed inflammatory cell death. Conclusion: HYSJ unguent enhances lymphangiogenesis, protects lymphatic endothelial cells in a high-glucose inflammatory environment, and accelerates DCW healing by suppression of TLR2/Myd88/caspase-1 signaling pathway. These findings provide important experimental support for the pharmacological mechanism by which HYSJ unguent facilitates healing of DCWs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.